gsk201410036k.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending October 2014
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--



GlaxoSmithKline plc
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
In accordance with DTR 3.1.4R(1)(a) and (c) GlaxoSmithKline plc ('GSK') was advised on 3 October 2014, of changes in the interests of the following Directors, Persons Discharging Managerial Responsibility and Connected Persons, arising from the purchase of Ordinary Shares of GSK on 2 October 2014, at a price of 1415.94 pence per Ordinary Share, as a result of the reinvestment of dividends paid on Ordinary Shares held in the GlaxoSmithKline ShareReward Plan.
 
Director/PDMR
Ordinary Shares
Sir Andrew Witty
36
Mr S Dingemans
10
Mr R G Connor
44
Mr S A Hussain
9
Mr D S Redfern
52
Ms C Thomas
52
Mr P C Thomson
24
Dr P J T Vallance
29
Ms E Walmsley
5
Mrs V A Whyte
34
 
Connected person
Ordinary Shares
Mrs K Thomson (Connected person of Mr P C Thomson)
14
 
 
V A Whyte
Company Secretary
 
3 October 2014

 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: October 03, 2014 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc